IRMDHealthcare · Medical DevicesThe 3 Wall Street analysts covering IRadimed Corp. hold a median 12-month price target of $118 — +33.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 81 of 100 as at 3 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores IRadimed Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (99): The share price has been relatively steady.
Accruals (39): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on IRMD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +33.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 Sept 2026 | Needham | Initiates | Hold | — |
| 2 Apr 2026 | Freedom Broker | Initiates | Buy | $116 |
| 2 Apr 2026 | Freedom Broker | Initiates | Buy | — |
| 14 Feb 2025 | Roth MKM | Reiterates | Buy | — |
| 2 Aug 2024 | Roth MKM | Maintains | Buy | — |
| 22 Apr 2024 | Roth MKM | Reinstates | Buy | $65 |
| 2 Aug 2021 | Roth Capital | Maintains | Buy | — |
| 31 July 2017 | Roth Capital | Upgrade | Buy | — |
| 5 Oct 2016 | Roth Capital | Downgrade | Neutral | — |
| 4 Apr 2016 | Roth Capital | Maintains | Buy | — |
| 16 June 2015 | Roth Capital | Maintains | Buy | — |
| 11 Aug 2014 | Roth Capital | Initiates | — | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
IRMD appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, IRadimed Corp. returned +3.5% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 17% of US stocks
Cheaper than 12% of US stocks
Cheaper than 9% of US stocks
Cheaper than 8% of US stocks
Higher than 62% of US stocks
Higher than 56% of US stocks
Higher than 86% of US stocks
Higher than 89% of US stocks
Higher than 87% of US stocks
Higher than 84% of US stocks
Higher than 97% of US stocks
Higher than 71% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
IRadimed Corp. has a market value of $1.0B and an enterprise value of $952.3M.
Revenue in the twelve months to 30 June 2026: $86.3M. The latest quarter grew 14.2% year on year.
Net income over the same four quarters: $23.1M, a 26.7% net margin.
Diluted earnings per share, trailing twelve months: $1.79.
Free cash flow in the twelve months to 30 June 2026: $24.5M, after $572K of capital spending.
IRadimed Corp. spent $15.8M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 42.5×; forward P/E: 32.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 1.01%, paying out 41% of earnings.
IRadimed Corp. employs 166 people — $520K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own IRadimed Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
iRadimed reported record third-quarter revenue as shipments of its newly launched 3870 MR IV pump accelerated. The company said it is moderating the production ramp to protect product quality.
Why it matters — IRMD watchers may note both the accelerating shipments and the company’s emphasis on maintaining product quality as production increases.
Seeking Alpha published a transcript of IRADIMED Corporation’s Q3 2026 earnings call. The excerpt provides no details from the call.
Why it matters — IRMD watchers may note the transcript’s publication, but the provided excerpt contains no information about the company’s results or outlook.
IRADIMED reported third-quarter 2026 revenue of $24.2 million, up 14% year over year and 18% from the second quarter. GAAP diluted EPS was $0.51 and non-GAAP diluted EPS was $0.55, compared with $0.41 and $0.47, respectively, in the second quarter.
Why it matters — The report gives IRMD watchers an update on quarterly revenue growth and diluted earnings.
Riverwater’s Small Cap strategy slightly underperformed the Russell 2000 in Q3 2026, as small-cap stocks broadly declined. The strategy initiated a position in IRadimed at the start of the quarter, replacing Talkspace after its acquisition.
Why it matters — The update reports Riverwater’s new IRMD position, but provides no further details about the investment.
IRADIMED said it will release its third-quarter 2026 financial results before the market opens on October 30, 2026. Management will hold a conference call at 11:00 a.m. Eastern Time that day to discuss the results and answer questions.
Why it matters — IRMD watchers can note the date and time for the company’s quarterly results release and management discussion.
The 3 Wall Street analysts covering IRadimed Corp. have a median 12-month price target of $118, with estimates ranging from $116 to $120. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering IRadimed Corp., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IRadimed Corp. 81 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, IRadimed Corp. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +33.2% from the last close, and Ticker Nerd's factor model ranks IRadimed Corp. 81 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering IRadimed Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IRMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $116 to $120 over the next 12 months.
IRadimed Corp. returned +3.5% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
iRadimed Corporation is a medical device company that develops, manufactures, markets, and distributes MRI-compatible patient care solutions. Its product portfolio includes MRI-compatible intravenous infusion pump systems, patient vital signs monitoring systems, ferromagnetic detection devices, and related accessories and disposables designed for use in magnetic resonance imaging environments.
The most recent item we track (MarketBeat, 30 Oct 2026): "What iRadimed (IRMD) Said on Its Q3 Earnings Call". iRadimed reported record third-quarter revenue as shipments of its newly launched 3870 MR IV pump accelerated. The company said it is moderating the production ramp to protect product quality.
iRadimed Corporation is a medical device company that develops, manufactures, markets, and distributes MRI-compatible patient care solutions. Its product portfolio includes MRI-compatible intravenous infusion pump systems, patient vital signs monitoring systems, ferromagnetic detection devices, and related accessories and disposables designed for use in magnetic resonance imaging environments. The company’s products are used by hospitals, acute care facilities, and outpatient imaging centers to support patient monitoring and medication delivery during MRI procedures. iRadimed Corporation focuses on equipment engineered with non-magnetic components to help maintain clinical workflow and patient safety in high-field imaging settings. Headquartered in Orlando, Florida, iRadimed Corporation serves customers in the United States and internationally through a specialized medical technology platform centered on MRI-compatible care.
CEO Mr. Roger E. Susi · 166 employees · United States · https://www.iradimed.com
